Atezolizumab/bevacizumab for the management of HCC in 1st setting – Arndt Vogel

🔥 off the press: Atezolizumab/bevacizumab for the management of HCC in 1st setting: systematic literature review & meta-analysis Gastroenterology,Karger Liver cancer.

👉 Individual comparisons suggest improved PFS/OS with Atezo/Bev vs most, but not all comparators.

For the article: Click here
Source: Arndt Vogel / Twitter

Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.